Azienda Ospedaliero-Universitaria di Parma
Quick facts
Phase 3 pipeline
- Metformin-Sitagliptin-Empaglifozin-Pioglitazone · Diabetes
This four-drug combination targets multiple pathways in glucose metabolism: metformin reduces hepatic glucose production, sitagliptin enhances incretin signaling, empaglifozin increases urinary glucose excretion, and pioglitazone improves insulin sensitivity.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Ospedaliero-Universitaria di Parma portfolio CI brief
- Azienda Ospedaliero-Universitaria di Parma pipeline updates RSS
Frequently asked questions about Azienda Ospedaliero-Universitaria di Parma
What is Azienda Ospedaliero-Universitaria di Parma's pipeline?
Azienda Ospedaliero-Universitaria di Parma has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Metformin-Sitagliptin-Empaglifozin-Pioglitazone.
Related
- Sector hub: All tracked pharma companies